SAN DIEGO, March 4, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its subsidiaries HempMeds® and Phyto Animal Health will be attending and exhibiting at Natural Products Expo West at the Anaheim Convention Center in Anaheim, CA on March 6-8, 2019. There, HempMeds® will be revealing its newest cannabidiol (CBD) product line.
According to a new analysis by Cowen & Co., it is predicted that the CBD market alone could reach $16 billion by 2025. The analysis also found nearly 7 percent of Americans are already using CBD and that, compounded with the passage of the 2018 Farm Bill in December 2018, it could be possible for us to see 25 million consumers using CBD in less than 10 years.
"Our attendance at this event is just one example of how HempMeds plans to reach a broader audience of business professionals and consumers this year," said HempMeds® President Todd Morrow. "As the legal CBD market grows exponentially in 2019, we plan to stay on the forefront of innovation and take new measures to increase CBD access for consumers around the world."
Natural Products Expo West, produced by New Hope Network, is the world's largest natural, organic and healthy products event. In 2018, the show had more than 85,000 attendees, including industry pioneers and new entrepreneurs, and brought in more than 3,500 exhibiting companies.
At the event, HempMeds® will be sponsoring a booth to exhibit the company's portfolio of trusted and reputable CBD products including its Real Scientific Hemp Oil™ (RSHO™) and Dixie Botanicals CBD tinctures, topicals, edibles and vapes.
The company will also be showcasing a soon-to-be-released personal care line that features many exciting CBD hemp products!
HempMeds® was the first company to ever bring hemp-based CBD oil products to market in the U.S. in 2012 and was the first to both make CBD products available in bulk for U.S. consumers. HempMeds® was also the first-ever company to receive historic federal government import approvals for its CBD products in the nations of Argentina, Brazil, Mexico and Paraguay.
Phyto Animal Health CEO Ian Quinn and his dog Dante the Pitt Bull, who takes CBD, will also be at the HempMeds® booth showcasing the company's line of CBD hemp oil supplements and hemp products for cats, dogs and horses. CBD hemp oil has been researched by top veterinarians for cardiovascular, pain management, orthopedic, and mental health in animals.
The following executives will be at the booth available for interview:
- March 6 – 12:00 p.m. to 3:00 p.m.: Medical Marijuana, Inc. CEO Dr. Stuart Titus
- March 6-8 – 11:00 a.m. to 1:00 p.m. & 3:00 p.m. to 5:00 p.m.: Phyto Animal Health CEO Ian Quinn and Dante the Pitt Bull
- March 7 – 1:00 p.m. to 4:00 p.m. and March 8 11:00 a.m.- 1:00 p.m.: HempMeds® President Todd Morrow
Visit booth #H933 and contact email@example.com to schedule any on-site interviews.
About Phyto Animal Health
As a company that cares about the health and wellbeing of all animals, Phyto Animal Health also cares about the earth. Using the least amount of water and other resources to create its products, the Company aims to leave the smallest footprint possible while helping provide cats, dogs and horses with the nutritional support they need to have outstanding mental and physical health.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
SOURCE Medical Marijuana, Inc.